ClinicalTrials.gg
CompletedNCT00225277PERISCOPEUpdated Feb 28, 2012Results posted

Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus

A Phase 3 interventional study of Pioglitazone and Glimepiride in Diabetes Mellitus, sponsored by Takeda. Completed at 79 sites in 4 countries. Open to participants aged 35 Years to 85 Years. Per ClinicalTrials.gov, last updated 2012-02-28.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's title name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
547
Allocation
Randomized
Ages
35 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 — 7 open to participants now, 8 under way, 1 of them phase 3. Pioglitazone · Diabetes Mellitus, Type 2.

Enrollment
16th of 122
547 · median 103
Started
2003
with 5 others
Phase 3
31 of 122
1 open now
Registered
8th of 122
by date
Lead sponsor
27 of 122
Takeda

Among the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, this one is the 16th largest by enrollment, is one of 6 that started in 2003, is one of 31 in phase 3, and was the 8th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About pioglitazone

Pioglitazone: first FDA approval 1999 (ACTOS), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 35 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study was to determine the efficacy of pioglitazone, once daily (QD), compared to glimepiride on atherosclerotic disease measured by intravascular ultrasound.

Read the detailed description

Diabetes is a chronic disease with multiple metabolic defects that result in hyperglycemia arising from inadequate insulin activity. Type 2 diabetes is usually the result of a progression from reduced sensitivity of hepatic and peripheral tissue cells to circulating insulin (ie, insulin resistance) to a progressive inability of the body to produce adequate insulin to overcome insulin resistance (ie, insulin deficiency due to beta-cell insufficiency) resulting in impaired glucose tolerance and ultimately overt diabetes. In the United States, an estimated 21 million people have diabetes, with type 2 diabetes occurring in approximately 90% to 95% of cases. The goal of treating type 2 diabetes is to control blood glucose and thereby prevent long-term complications. Adequate glycemic control is paramount in attempting to avert chronic complications, including blindness; renal dysfunction resulting in dialysis or renal transplantation; neuropathy; non-traumatic amputations; and macrovascular complications, including myocardial ischemia and myocardial infarction, stroke, and peripheral arterial disease. Intensive glucose management in the early stages of diabetes may help forestall such complications.

Therapeutic agents have been developed to address each of the major functional metabolic defects associated with type 2 diabetes: decreased beta-cell function, elevated hepatic glucose output, and insulin resistance. Thiazolidinediones increase glucose utilization, decrease gluconeogenesis, and increase glucose disposal by binding to nuclear receptors known as peroxisome proliferator-activated receptors. Thiazolidinediones reduce insulin resistance by enhancing insulin sensitivity in muscle cells, adipose tissue, and hepatic cells (inhibiting hepatic gluconeogenesis), with no direct impact on insulin secretion. Thus, thiazolidinediones improve glycemic control and result in reduced levels of circulating insulin without predisposing patients to hypoglycemia. Peroxisome proliferator-activated receptors are found in tissues important for insulin action, such as adipose tissue, skeletal muscle, and the liver. The greatest concentration of peroxisome proliferator-activated receptors-gamma receptors is in adipose tissue.

This study was designed to compare the effects of pioglitazone compared to glimepiride on progression of atherosclerotic disease, as measured by intravascular ultrasound.

03

Conditions studied

  • Diabetes Mellitus

Keywords

  • Glucose Metabolism Disorder
  • Dysmetabolic Syndrome
  • Type II Diabetes
  • Diabetes Mellitus, Lipoatrophic
  • Dyslipidemia
  • Drug Therapy
  • Atherosclerosis
04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 547 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
35 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females of who were sexually active agreed to use adequate , and can neither be pregnant nor lactating from Screening throughout the duration of the study.
  • Had a diagnosis of type 2 diabetes mellitus
  • Have received appropriate counseling on lifestyle modification for type 2 diabetes, including diet and exercise.
  • naïve to or was not currently taking antidiabetic therapy, or were currently treated with monotherapy or combination therapy.
  • Had a glycosylated level greater than or equal to 6.0% and less than 9% at screening if taking antidiabetic medication or greater than or equal to 6.5% and less than 10% at screening if naive to or not taking antidiabetic medication.
  • Angiographic criteria:

    • Entire Coronary Circulation: must have angiographic evidence of coronary heart disease as defined by at least 1 lesion in a native coronary artery that has greater than or equal to 20% reduction in lumen diameter by angiographic visual estimation.
    • Left Main Coronary Artery: must not have greater than 50% reduction in lumen diameter by visual angiographic estimation.
    • Target Coronary Artery:

      • The target vessel, which includes the main artery and all of its side branches, had not undergone prior percutaneous coronary intervention or coronary artery bypass graft surgery.
      • The target vessel, which includes the main artery and all of its side branches, was not currently a candidate for intervention or a likely candidate for intervention over the next 72 weeks.
      • The target vessel was not a bypass graft.
      • The target vessel was not infarct related.
  • Had previous coronary artery bypass surgery at least six weeks prior to the qualifying intravascular ultrasound are eligible provided they are stable and meet all other entry criteria.
  • Had an intravascular ultrasound tape deemed to be of acceptable intravascular ultrasound image quality and demonstrated adherence to the intravascular ultrasound interrogation protocol, as determined by the intravascular ultrasound Core Laboratory™ assessment.

Exclusion criteria

Exclusion Criteria:

  • Had type I diabetes mellitus.
  • Had participated in another study, or participated in an investigational study 30 days prior to the start of this study, or who were scheduled to participate in an investigational study during the time frame of this study.
  • Male subjects who had a serum creatinine level greater than or equal to 2.0 mg/dL (greater than or equal to 177 µmol/L) (greater than or equal to 1.5 mg/dL; [greater than or equal to 133 µmol /L] if taking metformin) and female subjects who have serum creatinine greater than or equal to 1.8 mg/dL [greater than or equal to 159 µmol /L] (greater than or equal to 1.4 mg/dL [greater than or equal to 124 µmol /L] if taking metformin).
  • Had unexplained microscopic hematuria greater than +1, confirmed by repeat testing.
  • Had a history of drug abuse or a history of alcohol abuse (defined as regular or daily consumption of more than 4 alcoholic drinks per day) within the past 2 years.
  • Had clinical cardiac failure as defined by class III or IV, or known left ventricular dysfunction measured as less than 40%, or by current use of diuretics or angiotensin converting enzyme inhibitors for treatment of heart failure.
  • Had an level of greater than 2.5 times the active liver disease, or jaundice.
  • Had a greater than 48 kg/m2 as calculated by weight (kg)/height (m2) or weight (pounds)/height (inches) 2 x 703.
  • Was required to take or intended to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may have interfered with evaluation of the study medication, including:

    • Chronically used oral (eg, prednisone, cortisone, hydrocortisone, dexamethasone)
    • Niacin greater than100 mg a day, including niacin-containing products such as Advicor®
    • Chronically used steroid-joint injections
    • Thiazolidinediones
    • Sulfonylureas
    • Metformin/sulfonylurea combination
    • Other oral antidiabetic medications (eg, nateglinide [Starlix®], acarbose [Precose®]) with the exception of metformin
  • Had known or suspected or recurrence of malignancy within the past 5 years, with the exception of basal cell carcinoma and Stage 1 squamous cell carcinoma of the skin.
  • Had any disease where, in the opinion of the investigator (or designee), survival is expected to be less than 72 weeks.
  • Clinical status was unstable (ie, requiring vasopressors or intravenous inotropes, intra-aortic balloon pump, hypotension [systolic blood pressure less than 90 mm Hg]).
  • Prior to the screening visit, was scheduled for a staged cardiac intervention (percutaneous coronary intervention), peripheral vascular intervention, or coronary artery bypass graft surgery following the screening angiography.
  • In the opinion of the investigator (or designee) had valvular heart disease likely to require surgical repair/replacement during the course of the study.
  • Had persistent, uncontrolled hypertension (ie, sitting systolic blood pressure greater than 160 mm Hg or sitting diastolic blood pressure greater than 100 mm Hg) at randomization.
  • Males who had less than 10.5 g/dL (less than 105 g/L) and female subjects who had hemoglobin less than 10.0 g/dL (less than 100 g/L).
  • Had a triglyceride level greater than 500 mg/dL (greater than 5.6 mmol/L).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
547 participants (actual)

Study arms

  • Experimental
    Pioglitazone QD

    Drug: Pioglitazone

  • Active comparator
    Glimepiride QD

    Drug: Glimepiride

Interventions

  • Up to 45 mg pioglitazone (optimized for glucose control), tablets, orally, once daily for up to 72 weeks.

    Also known as: ACTOS®, AD4833

  • Up to 4 mg of glimepiride (optimized for glucose control), tablets, orally, once daily for up to 72 weeks.

07

What researchers measure

Primary outcomes

  1. Nominal Change From Baseline in Percent Atheroma Volume

    The nominal change from baseline in percent atheroma volume for all slices of anatomically comparable segments of the target coronary artery. Assessment completed at the Week 72 visit or Final Visit if treatment was prematurely discontinued.

    Time frame: Baseline and Final Visit (up to 72 weeks)

Secondary outcomes

  1. Nominal Change From Baseline in Normalized Total Atheroma Volume

    The nominal change in normalized total atheroma volume as measured by the average of plaque areas for all slices of anatomically comparable segments of the target coronary artery multiplied by the mean number of matched slices in the population. Assessment completed at the Week 72 visit or Final Visit if treatment was prematurely discontinued.

    Time frame: Baseline and Final Visit (up to 72 weeks)

  2. Number of Subjects Experiencing Any of the Composite Endpoint A Cardiovascular Events

    Due to low event rates, number of subjects experiencing any of the composite endpoint A cardiovascular events is being reported instead of time to first occurrence. Endpoint A conditions listed in Limitations and Caveats section.

    Time frame: Up to 72 weeks

  3. Number of Subjects Experiencing Any of the Composite Endpoint B Cardiovascular Events

    Due to low event rates, number of subjects experiencing any of the composite endpoint B cardiovascular events is being reported instead of time to first occurrence. Endpoint B conditions listed in Limitations and Caveats section.

    Time frame: Up to 72 weeks

  4. Number of Subjects Experiencing Any of the Composite Endpoint C Cardiovascular Events

    Due to low event rates, number of subjects experiencing any of the composite endpoint C cardiovascular events is being reported instead of time to first occurrence. Endpoint C conditions listed in Limitations and Caveats section.

    Time frame: Up to 72 weeks

Other outcomes

  1. Number of Cardiovascular Events as Adjudicated by the Clinical Endpoint Committee

    The incidence of cardiovascular events and composite endpoints occurring within 30 days of last dose as adjudicated by the Clinical Endpoint Committee. Abbreviations: PCI: Percutaneous Coronary Intervention; CABG: Coronary Artery Bypass Graft; CHF: Congestive Heart Failure.

    Time frame: Up to 72 weeks

08

Results

Posted Jun 10, 2009
Limitations and caveats
Composite Endpoints A,B,C include cardiovascular mortality, nonfatal MI and nonfatal stroke. In addition, B: coronary revascularization, carotid endarterectomy/stenting, unstable angina hosp. or CHF; C: hospitalization for unstable angina or CHF.

Participant flow

Subjects were enrolled at 97 sites in the United States, Canada, Argentina and Chile from 21 July 2003 to 18 October 2007.

Participant flow — Overall Study
MilestonePioglitazone QDGlimepiride QD
Started274273
Completed177178
Not completed9795
Withdrew: Adverse event3034
Withdrew: Lack of efficacy41
Withdrew: Lost to follow-up46
Withdrew: Physician decision68
Withdrew: Protocol violation63
Withdrew: Withdrawal by subject4034
Withdrew: Other79

Outcome measures

PrimaryNominal Change From Baseline in Percent Atheroma Volume

The nominal change from baseline in percent atheroma volume for all slices of anatomically comparable segments of the target coronary artery. Assessment completed at the Week 72 visit or Final Visit if treatment was prematurely discontinued.

Time frame:
Baseline and Final Visit (up to 72 weeks)
Reported as:
Least squares mean · Percent volume
Nominal Change From Baseline in Percent Atheroma Volume
Percent volumePioglitazone QDGlimepiride QD
Baseline40.592 ± 0.692540.016 ± 0.6663
Nominal Change from Baseline-0.161 ± 0.20950.725 ± 0.2017
Statistical analysis
  • Pioglitazone QD vs Glimepiride QD · ANCOVA · p = 0.002 · Mean difference (final values): -0.886 · 95% CI -1.4480 to -0.3250Mean Difference = Pioglitazone - Glimepiride
SecondaryNominal Change From Baseline in Normalized Total Atheroma Volume

The nominal change in normalized total atheroma volume as measured by the average of plaque areas for all slices of anatomically comparable segments of the target coronary artery multiplied by the mean number of matched slices in the population. Assessment completed at the Week 72 visit or Final Visit if treatment was prematurely discontinued.

Time frame:
Baseline and Final Visit (up to 72 weeks)
Reported as:
Least squares mean · Percent volume
Nominal Change From Baseline in Normalized Total Atheroma Volume
Percent volumePioglitazone QDGlimepiride QD
Baseline206.579 ± 7.2778217.619 ± 7.0030
Nominal Change from Baseline-5.528 ± 1.5989-1.480 ± 1.5370
Statistical analysis
  • Pioglitazone QD vs Glimepiride QD · ANCOVA · p = 0.064 · Mean difference (final values): -4.048 · 95% CI -8.3336 to 0.2374Mean Difference = Pioglitazone - Glimepiride
SecondaryNumber of Subjects Experiencing Any of the Composite Endpoint A Cardiovascular Events

Due to low event rates, number of subjects experiencing any of the composite endpoint A cardiovascular events is being reported instead of time to first occurrence. Endpoint A conditions listed in Limitations and Caveats section.

Time frame:
Up to 72 weeks
Reported as:
Number · Participants
Number of Subjects Experiencing Any of the Composite Endpoint A Cardiovascular Events
ParticipantsPioglitazone QDGlimepiride QD
Number of Subjects Experiencing Any of the Composite Endpoint A Cardiovascular Events5 (0 to 0)6 (0 to 0)
Statistical analysis
  • Pioglitazone QD vs Glimepiride QD · Log Rank · p = 0.744 (Kaplan-Meier methodology was used to estimate the time to event for each composite endpoint. The p-value was based on a log-rank test.)
SecondaryNumber of Subjects Experiencing Any of the Composite Endpoint B Cardiovascular Events

Due to low event rates, number of subjects experiencing any of the composite endpoint B cardiovascular events is being reported instead of time to first occurrence. Endpoint B conditions listed in Limitations and Caveats section.

Time frame:
Up to 72 weeks
Reported as:
Number · Participants
Number of Subjects Experiencing Any of the Composite Endpoint B Cardiovascular Events
ParticipantsPioglitazone QDGlimepiride QD
Number of Subjects Experiencing Any of the Composite Endpoint B Cardiovascular Events40 (0 to 0)41 (0 to 0)
Statistical analysis
  • Pioglitazone QD vs Glimepiride QD · Log Rank · p = 0.883 (Kaplan-Meier methodology was used to estimate the time to event for each composite endpoint. The p-value was based on a log-rank test.)
SecondaryNumber of Subjects Experiencing Any of the Composite Endpoint C Cardiovascular Events

Due to low event rates, number of subjects experiencing any of the composite endpoint C cardiovascular events is being reported instead of time to first occurrence. Endpoint C conditions listed in Limitations and Caveats section.

Time frame:
Up to 72 weeks
Reported as:
Number · participants
Number of Subjects Experiencing Any of the Composite Endpoint C Cardiovascular Events
participantsPioglitazone QDGlimepiride QD
Number of Subjects Experiencing Any of the Composite Endpoint C Cardiovascular Events11 (0 to 0)13 (0 to 0)
Statistical analysis
  • Pioglitazone QD vs Glimepiride QD · Log Rank · p = 0.663 (Kaplan-Meier methodology was used to estimate the time to event for each composite endpoint. The p-value was based on a log-rank test.)
Other pre-specifiedNumber of Cardiovascular Events as Adjudicated by the Clinical Endpoint Committee

The incidence of cardiovascular events and composite endpoints occurring within 30 days of last dose as adjudicated by the Clinical Endpoint Committee. Abbreviations: PCI: Percutaneous Coronary Intervention; CABG: Coronary Artery Bypass Graft; CHF: Congestive Heart Failure.

Time frame:
Up to 72 weeks
Reported as:
Number · Number of Events
Number of Cardiovascular Events as Adjudicated by the Clinical Endpoint Committee
Number of EventsPioglitazone QDGlimepiride QD
Nonfatal Myocardial Infarction24
Nonfatal Stroke01
Coronary Revascularization: PCI/CABG counted once2930
Coronary Revascularization: PCI2528
Coronary Revascularization: CABG52
Carotid Endarterectomy/Stenting10
Hospitalization for Unstable Angina42
CHF Hospitalization: new/exacerbated counted once45
Hospitalization for New CHF42
Hospitalization for Exacerbated CHF03
Noncardiovascular Mortality01
Cardiovascular Mortality31
Composite Endpoint A56
Composite Endpoint B4041
Composite Endpoint C1113

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pioglitazone QD———
Glimepiride QD———
Most frequent serious events
Showing 10 of 110
Most frequent serious events
EventPioglitazone QDGlimepiride QD
Coronary Artery DiseaseCardiac disorders20/27016/273
Non-Cardia Chest PainGeneral disorders15/2705/273
Angina PectorisCardiac disorders8/2704/273
Coronary Artery StenosisCardiac disorders5/2705/273
Cardiac Failure CongestiveCardiac disorders3/2705/273
PneumoniaInfections and infestations0/2705/273
Angina UnstableCardiac disorders4/2703/273
Myocardial InfarctionCardiac disorders3/2702/273
Acute Coronary SyndromeCardiac disorders0/2703/273
Chronic Obstructive Airways Disease ExacerbatedRespiratory, thoracic and mediastinal disorders0/2703/273
Most frequent other events
Showing 10 of 18
Most frequent other events
EventPioglitazone QDGlimepiride QD
HypoglycaemiaMetabolism and nutrition disorders41/270100/273
Oedema PeripheralGeneral disorders48/27030/273
Angina PectorisCardiac disorders12/27030/273
Weight IncreasedInvestigations28/27015/273
Non-Cardiac Chest PainGeneral disorders21/27027/273
DizzinessNervous system disorders26/27020/273
HypertensionVascular disorders13/27024/273
NasopharyngitisInfections and infestations13/27022/273
HeadacheNervous system disorders19/27017/273
Pain In ExtremityMusculoskeletal and connective tissue disorders15/27019/273

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Pioglitazone QDGlimepiride QDTotal
<=18 years000
Between 18 and 65 years189193382
>=65 years8180161
Sex: Female, Male
Sex: Female, Male(Participants)Pioglitazone QDGlimepiride QDTotal
Female8493177
Male186180366
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pioglitazone QDGlimepiride QDTotal
Hispanic or Latino6371134
Not Hispanic or Latino207202409
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Pioglitazone QDGlimepiride QDTotal
Native American31013
Asian121628
Black or African American302757
White225220445
Family History of Coronary Artery Disease
Family History of Coronary Artery Disease(Participants)Pioglitazone QDGlimepiride QDTotal
Male Relative History9177168
Female Relative History6059119
No Family History119137256
Body Mass Index
Body Mass Index(Kg/m squared)Pioglitazone QDGlimepiride QDTotal
Mean32.08 ± 5.26432.03 ± 5.23332.05 ± 0
Duration of Coronary Artery Disease
Duration of Coronary Artery Disease(Months)Pioglitazone QDGlimepiride QDTotal
Mean40.4 ± 65.1040.5 ± 67.2040.4 ± 0
Duration of Diabetes Mellitus
Duration of Diabetes Mellitus(Months)Pioglitazone QDGlimepiride QDTotal
Mean98.0 ± 100.2596.3 ± 89.5197.1 ± 0
09

Study locations

79 sites
  • Birmingham, Alabama, United States
  • Phoenix, Arizona, United States
  • Huntington Beach, California, United States
  • Los Angeles, California, United States
  • Sacramento, California, United States
  • San Diego, California, United States
  • Torrance, California, United States
  • Bridgeport, Connecticut, United States
  • Farmington, Connecticut, United States
  • Washington, District of Columbia, United States
  • Bay Pines, Florida, United States
  • Jacksonville, Florida, United States
  • Decatur, Georgia, United States
  • Boise, Idaho, United States
  • Chicago, Illinois, United States
  • Edgewood, Kentucky, United States
  • Lexington, Kentucky, United States
  • Louisville, Kentucky, United States
  • New Orleans, Louisiana, United States
  • Bangor, Maine, United States
  • Baltimore, Maryland, United States
  • Detroit, Michigan, United States
  • Flint, Michigan, United States
  • Kalamazoo, Michigan, United States
  • Petoskey, Michigan, United States
  • Pontiac, Michigan, United States
  • Royal Oak, Michigan, United States
  • Ypsilanti, Michigan, United States
  • Duluth, Minnesota, United States
  • Minneapolis, Minnesota, United States
  • St. Cloud, Minnesota, United States
  • Columbia, Missouri, United States
  • Camden, New Jersey, United States
  • Albany, New York, United States
  • Bronx, New York, United States
  • Mineola, New York, United States
  • New York, New York, United States
  • Rochester, New York, United States
  • Troy, New York, United States
  • West Islip, New York, United States
  • Williamsville, New York, United States
  • Winston-Salem, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Cleveland, Ohio, United States
  • Columbus, Ohio, United States
  • Westlake, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Tulsa, Oklahoma, United States
  • Abington, Pennsylvania, United States
  • Bryn Mawr, Pennsylvania, United States
  • Hershey, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • Providence, Rhode Island, United States
  • Greenville, South Carolina, United States
  • Memphis, Tennessee, United States
  • Oak Ridge, Tennessee, United States
  • Amarillo, Texas, United States
  • Houston, Texas, United States
  • Lubbock, Texas, United States
  • San Antonio, Texas, United States
  • Charlottesville, Virginia, United States
  • Norfolk, Virginia, United States
  • Richmond, Virginia, United States
  • Everett, Washington, United States
  • Green Bay, Wisconsin, United States
  • Ciudad de Buenos Aires, Argentina
  • Cordoba, Argentina
  • Quilmes, Argentina
  • Edmonton, Alberta, Canada
  • Vancouver, British Columbia, Canada
  • Victoria, British Columbia, Canada
  • Winnepeg, Manitoba, Canada
  • Saint John, New Brunswick, Canada
  • London, Ontario, Canada
  • Ottawa, Ontario, Canada
  • Montreal, Quebec, Canada
  • Sainte Foy, Quebec, Canada
  • Saskatoon, Saskatchewan, Canada
  • Santiago, Chile
10

References and documents

Publications

  • Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, Jure H, De Larochelliere R, Staniloae CS, Mavromatis K, Saw J, Hu B, Lincoff AM, Tuzcu EM; PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008 Apr 2;299(13):1561-73. doi: 10.1001/jama.299.13.1561. Epub 2008 Mar 31. PubMed 18378631 ↗
  • Betteridge DJ. CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone. Fundam Clin Pharmacol. 2009 Dec;23(6):675-9. doi: 10.1111/j.1472-8206.2009.00741.x. Epub 2009 Sep 10. PubMed 19744248 ↗
  • Nicholls SJ, Tuzcu EM, Wolski K, Bayturan O, Lavoie A, Uno K, Kupfer S, Perez A, Nesto R, Nissen SE. Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study. J Am Coll Cardiol. 2011 Jan 11;57(2):153-9. doi: 10.1016/j.jacc.2010.06.055. PubMed 21211686 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2003, a primary completion of Oct 2007 and a completion of Oct 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2009, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2005
First posted
Sep 23, 2005
Start
Jul 2003
Primary completionActual
Oct 2007
CompletionActual
Oct 2007
Results first posted
Jun 10, 2009
Last update
Feb 28, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00225277
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Sep 23, 2005
Start date
Jul 2003
Primary completion
Oct 2007
Completion
Oct 2007
Results posted
Jun 10, 2009
Last update
Feb 28, 2012

Study contacts

VP Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pioglitazone

Start the discussion